Answers are grounded in this paper and cite their sources.
In Brief BACKGROUND: Mycophenolate mofetil has teratogenic properties in rats and rabbits. Previous human studies have reported an increased rate of fetal losses with its use. We report a case of major fetal malformations due to mycophenolate mofetil. CASE: The patient was treated with mycophenolate mofetil before conception and during the first trimester of pregnancy. The fetus had multiple malformations, specifically, facial dysmorphology and midline anomalies, including agenesis of the corpus callosum. CONCLUSION: This case of fetal malformation attributable to mycophenolate mofetil must be taken into consideration when considering pregnancy in an organ-transplant recipient. We report a case of human fetal malformations attributable to mycophenolate mofetil, an immunosuppressant drug that is increasingly used after organ transplantation.
No takes yet. Share an insight, caveat, or question.
Ray et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: